DexCom, Inc.

NasdaqGS:DXCM Stock Report

Market Cap: US$31.3b

DexCom Future Growth

Future criteria checks 4/6

DexCom is forecast to grow earnings and revenue by 16.6% and 13.2% per annum respectively. EPS is expected to grow by 15.9% per annum. Return on equity is forecast to be 26.7% in 3 years.

Key information

16.6%

Earnings growth rate

15.9%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate13.2%
Future return on equity26.7%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

DexCom: Brighter 2025 From Stelo Ramp

Dec 10

Is It Too Late To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Dec 05
Is It Too Late To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?

Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

Nov 08
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

DexCom Growing Into Its Valuation, But Still No Bargain

Oct 25

DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

Oct 21
DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Oct 16

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Sep 30
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom: Investors Discounting Long CGM Growth Runway

Sep 19

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Sep 16
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom Q2 Earnings: Traditional Market Overreaction

Aug 07

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

Jul 26
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Jul 26

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

Jul 12
Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

Jul 03

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Jun 28
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Jun 03
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dexcom: Positive Catalysts Ahead To Support Growth

May 13

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

May 07
If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

May 06

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Apr 25
Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Earnings and Revenue Growth Forecasts

NasdaqGS:DXCM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,2969511,0011,37721
12/31/20254,5997807981,13924
12/31/20244,01663460393624
9/30/20243,954681535822N/A
6/30/20243,935667666891N/A
3/31/20243,802639584802N/A
12/31/20233,622542512749N/A
9/30/20233,403377500747N/A
6/30/20233,198358466771N/A
3/31/20233,023293416754N/A
12/31/20222,910341305670N/A
9/30/20222,793244261643N/A
6/30/20222,673230216597N/A
3/31/20222,57225895486N/A
12/31/20212,44921753443N/A
9/30/20212,319577140509N/A
6/30/20212,170562101409N/A
3/31/20212,027530236502N/A
12/31/20201,927550277476N/A
9/30/20201,821231264447N/A
6/30/20201,716205209394N/A
3/31/20201,601148131305N/A
12/31/20191,476101135315N/A
9/30/20191,351-17151205N/A
6/30/20191,222-17039167N/A
3/31/20191,128-13053144N/A
12/31/20181,032-12756123N/A
9/30/20189154364131N/A
6/30/2018833-5N/A110N/A
3/31/2018761-33N/A83N/A
12/31/2017719-50N/A92N/A
9/30/2017669-48N/A64N/A
6/30/2017633-65N/A51N/A
3/31/2017599-88N/A57N/A
12/31/2016573-66N/A56N/A
9/30/2016533-57N/A54N/A
6/30/2016490-80N/A49N/A
3/31/2016445-64N/A45N/A
12/31/2015402-58N/A49N/A
9/30/2015356-58N/A46N/A
6/30/2015319-20N/A40N/A
3/31/2015285-23N/A29N/A
12/31/2014259-22N/A24N/A
9/30/2014227-26N/A20N/A
6/30/2014201-27N/A10N/A
3/31/2014178-31N/A5N/A
12/31/2013160-30N/A2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DXCM's forecast earnings growth (16.6% per year) is above the savings rate (2.6%).

Earnings vs Market: DXCM's earnings (16.6% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: DXCM's earnings are forecast to grow, but not significantly.

Revenue vs Market: DXCM's revenue (13.2% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: DXCM's revenue (13.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DXCM's Return on Equity is forecast to be high in 3 years time (26.7%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:14
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DexCom, Inc. is covered by 63 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James Francis MainwaringAtlantic Equities LLP
Anand VankawalaAvondale Partners
null nullBaird